B O O K - American College of Rheumatology

tuesday
88
Upon completion of this session, participants should be able to:
• describe appropriate autoantibody testing requests and
interpretation of results relevant to an early diagnosis and
management of RA
• identify the clinical value of measuring IgA RF in RA
• describe the predictive value of RA marker antibodies
• review the current status of “inaccurate ANA results”
A412
Behçet’s Disease
Moderators: Yoshiaki Ishigatsubo, MD; Yokohama City Graduate
School of Medicine; Yokohama, Japan
Ahmet Gul, MD; Istanbul University; Istanbul, Turkey
6:45 PM
Genomewide Association Studies in Behçet’s Disease
Daniel L. Kastner, MD, PhD; NIAMS, NIH; Bethesda, MD
7:00 PM
HLA-B51 and Behçet’s Disease
Yeong W. Song, MD; Seoul National University Hospital; Seoul,
Republic of Korea
7:15 PM
Immunological Features of Behçet’s Disease
Mitsuhiro Takeno, MD, PhD; Yokohama City University, Japan
7:30 PM
Vascular Involvement in Behçet’s Disease
Dorian O. Haskard, DM; Imperial College; London, United
Kingdom
7:45 PM
Unmet Needs and Clinical Trials in Behçet’s Disease
Ahmet Gul, MD; Istanbul University; Istanbul, Turkey
Session Overview:
Since the cause of Behçet’s Disease is still unknown, current
treatment is aimed at easing the symptoms, reducing
inflammation, and controlling the immune system. Recently,
new idea such as auto inflammatory disease has been induced
as the pathogenesis the disease. To understand current findings
is helpful to find new treatment for Behçet’s Disease. Although
Behçet’s Disease is common in the Middle East and Asia and
rare in the United State and other regions, new insights need to
be shared with the attendees so that everyone is aware of the
latest developments.
Upon completion of this session, participants should be able to:
• describe the genetic aspect of Behçet’s Disease
• discuss the immunological features of Behçet’s Disease
• analyze of the endothelial cells and vascular involvement in
Behçet’s Disease
• discuss unmet need and clinical trials in Behçet’s Disease
A406
Economic Evaluations
Moderators: Annemarie Braakman-Jansen, PhD; University of
Twente; Enschede, Netherlands
Mart A. van de Laar, MD; University Twente and Medisch
Sprectrum Twente; Enschede, Netherlands
6:45 PM
QALYs: Why use Them?
Nick Bansback, PhD; St. Paul’s Hospital; Vancouver, Canada
2010 Program Book
7:00 PM
QALYs: To Use or Not to Use
Deborah P. Symmons, MD; University of Manchester;
Manchester, United Kingdom
7:15 PM
The Patient’s Perspective
Laurien Buitinga, MSc; University of Twente, Enschede,
Netherlands; Enschede, Netherlands
7:30 PM
Much Ado About QALYs
Annelies Boonen, MD, PhD; Maastricht University Medical
Centre, Maastricht; Maastricht, Netherlands
7:45 PM
Discussion
Session Overview:
Economic evaluations are increasingly being used for decision
making regarding treatment for patients. There are different
methods for valuing health states in order to calculate “QALYs”
for use in cost utility analysis. These methods can lead to
very different results and might influence decision making.
Another key issue is that of whose preferences should be used
as the source of values: patients, doctors, decision-makers
or those of the general public? Which method and values a
researcher should use is dependent on the context of the
research question. Should the research guide a clinical or policy
decision? In this workshop the state of the art of health state
valuations and implications for future research within the field of
rheumatology will be interactively discussed with the audience.
Upon completion of this session, participants should be able to:
• describe how to value health states
• analyze different perspectives used in economic evaluations
• determine the proper valuation technique for use, based on
the context of the research question
• evaluate the use of tariffs
B313
Epidemiology of Axial Spondyloarthritis
Moderators: John D. Reveille, MD; University Texas Health
Science Center; Houston, TX
Michael H. Weisman, MD; Cedars-Sinai Medical Center; Los
Angeles, CA
6:45 PM
The GESPIC Experience
Martin Rudawaleit, MD; University Hospital Charité – Campus
Benjamin Franklin; Steglitz, Berlin, Germany
7:10 PM
Axial SpA in the US: The NHANES Survey
Rosemarie Hirsch, MD, MPH; CDC - National Center for Health
Statistics; Silver Spring, MD
7:35 PM
A Population Based Survey of Axial SpA in Mexico
R. Burgos Vargas, MD; Hospital General de Mexico; Mexico City,
Mexico
Upon completion of this session, participants should be able to:
• develop a better understanding of the presentation
epidemiology of axial spondyloarthritis in a prospectively
followed longitudinal cohort of patients from Germany
• review the new data from NHANES 2009 on the prevalence of
axial spondyloarthritis in the United States